Insulin-like growth factor-1 isoforms in rat hepatocytes and cholangiocytes and their involvement in protection against cholestatic injury

Laboratory Investigation

Volumn 88, Issue 9, 2008, Pages 986-994

  Gatto, Manuela ^a   Drudi Metalli, Veronica ^a   Torrice, Alessia ^a   Alpini, Gianfranco ^b   Cantafora, Alfredo ^a   Blotta, Ida ^a   Alvaro, Domenico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Bile salts; Cholangiocytes; Cholestasis; Hepatocytes; IGF1

Indexed keywords

GLYCOCHENODEOXYCHOLIC ACID; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; LIVER CELL; LIVER INJURY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT;

EID: 50249125914     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.63     Document Type: Article

References (49)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
2. Sepp-Lorenzino L. Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 1998;47:235-253.
3. Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 2001;142:1685-1688.
4. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-797.
5. Tumber A, Meikle MC, Hill PA. Autocrine signals promote osteoblast survival in culture. J Endocrinol 2000;167:383-390.
6. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856-2861.
7. Hong F, Kwon SJ, Jhun BS. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci 2001;68:1095-1105.
8. van Golen CM, Feldman EL. Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol 2000;182:24-32.
9. Chen H, Yan GC, Gishizky ML. Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor 1 receptors. Cell Growth Differ 1998;9:939-947.
10. O'Connor R, Kauffmann-Zeh A, Liu YM. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 1997;17:427-435.
11. Musaró A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195-200.
12. Hameed M, Orrell RW, Cobbold M, et al. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol 2003;547:247-254.
13. McCall GE, Allen DL, Haddad F, et al. Transcriptional regulation of IGF-I expression in skeletal muscle. Am J Cell Physiol 2003;285:C831-C839.
14. Wang X, Yang Y, Adamo ML. Characterization of the rat insulin-like growth factor I gene promoters and identification of a minimal exon 2 promoter. Endocrinol 1997;134:1528-1536.
15. Pfaffl MW, Mirkeva Georgieva T, Penchev Georgiev I, et al. Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in bovine species. Domest Anim Endocrinol 2002;22:91-102.
16. Barton ER, Morris L, Musaro A, et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002;157:137-148.
17. Aperghis M, Johnson IP, Cannon J, et al. Different levels of neuroprotection by two insulin-like growth factor-I splice variants. Brain Res 2004;1009:213-218.
18. Musaro A, Rosenthal N. Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I. Mol Cell Biol 1999;19:3115-3124.
19. Dobrowolny G, Giacinti C, Pelosi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005;17:193-199.
20. Barton-Davis ER, Shoturma DI, Musaró A, et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 1998;95:15603-15607.
21. Barton-Davis ER, Shoturma DI, Sweeney HL. Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand 1999;167:301-305.
22. Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-842.
23. Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 2001;142:1685-1688.
24. Adamo ML, Farrar RP. Resistance training, and IGF involvement in the maintenance of muscle mass during the aging process. Ageing Res Rev 2006;5:310-331.
25. DeBosch BJ, Baur E, Deo BK, et al. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation. J Neurochem 2001;77:1157-1167.
26. Meinel L, Zoidis E, Zapf J, et al. Localized insulin-like growth factor I delivery to enhance new bone formation. Bone 2003;33:660-672.
27. Alvaro D, Drudi-Metalli V, Alpini G, et al. The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol 2005;43:875-883.
28. Drudi Metalli V, Mancino MG, Mancino A, et al. Bile salts regulate proliferation and apoptosis of liver cells by modulating the IGF1 system. Dig Liver Dis 2007;39:654-662.
29. Gigliozzi A, Alpini G, Baroni GS, et al. Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology 2004;127:1198-1209.
30. Cantafora A, Blotta I, Rivabene R, et al. Evaluation of RNA messengers involved in lipid trafficking of human intestinal cells by reverse-transcription polymerase chain reaction with competimer technology and microchip electrophoresis. Electrophoresis 2001;24:3748-3754.
31. Introduction to quantitative PCR. Methods and application guide http://www.stratagene.com/.
32. Heidenreich S, Schmidt M, August C, et al. Regulation of human monocyte apoptosis by the CD14 molecule. J Immunol 1997;159:3178-3188.
33. Vera M, Sobrevals L, Zaratiegui M, et al. Liver transduction with a simian virus 40 vector encoding insulin-like growth factor I reduces hepatic damage and the development of liver cirrhosis. Gene Therapy 2007;14:203-210.
34. Lorenzo-Zuniga V, Rodriguez-Ortigosa CM, Bartoli R, et al. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut 2006;55:1306-1312.
35. Castilla-Cortazar I, Garcia M, Quiroga J, et al. Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology 2000;31:592-600.
36. Cemborain A, Castilla-Cortazar I, Garcia M, et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998;28:122-131.
37. Prieto J, Sobrevals L, Razquin N, et al. Treatment of established cirrhosis with SV40 vectors encoding insulin-like growth factor I. Hepatology 2007;46:S1, abstract.
38. Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005;43:630-666.
39. Alpini G, Lenzi R, Sarkozi L, et al. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 1988;81:569-578.
40. Buscher HP, Miltenberger C, MacNelly S, et al. The histoautoradiographic localization of taurocholate in rat liver after bile duct ligation. Evidence for ongoing secretion and reabsorption processes. J Hepatol 1989;8:181-191.
41. Muriel P, Gonzalez P. Liver damage induced by acute cholestasis in the rat is ameliorated partially by L-arginine. Comp Biochem Pysiol C pharmacol Toxicol Endocrinol 1998;120:421-424.
42. Souza ME, Castro-e-Silva Júnior O, Picinato MA, et al. Serum transaminase levels in the acute phase of chronic extrahepatic cholestasis. Braz J Med Biol Res 1990;23:995-997.
43. Georgiev P, Jochum W, Heinrich S, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg 2008;95:646-656.
44. Kim ND, Moon JO, Slitt AL, et al. Early growth response factor-1 is critical for cholestatic liver injury. Toxicol Sci 2006;90:586-595.
45. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007;132:415-431.
46. Guicciardi ME, Gores GJ. Cholestatic hepatocellular injury: what do we know and how should we proceed. J Hepatol 2005;42:297-300.
47. LeSage EG, Alvaro D, Benedetti A, et al. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology 1999;117:191-199.
48. 2+)-, and protein kinase C alpha-dependent mechanisms. Hepatology 2000;32:17-25.
49. Marzioni M, Glaser S, Francis H, et al. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 2005;128:121-137.